Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 2/20 | 0.47 |
| ▸ | NSD2 | O96028 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 5/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30853086 | 1.00 | APAF1 (0.47) | APAF1NSD2CASP3SENP8SENP7 | |
| SCHEMBL628689 | 0.94 | APAF1 (0.47) | APAF1NSD2CASP3SENP8SENP7 | |
| SCHEMBL5358941 | 0.86 | TNF (0.57) | APAF1NSD2CASP3SENP8SENP7 | |
| SCHEMBL31589356 | 0.86 | TNF (0.57) | APAF1NSD2CASP3SENP8SENP7 | |
| SCHEMBL16431495 | 0.82 | APAF1 (0.48) | APAF1NSD2CASP3SENP8SENP7 | |
| SCHEMBL6768992 | 0.81 | TNF (0.46) | APAF1NSD2CASP3SENP8SENP7 | |
| SCHEMBL15049245 | 0.81 | NSD2 (0.47) | APAF1NSD2CASP3SENP8SENP7 | |
| SCHEMBL29728760 | 0.81 | NSD2 (0.47) | APAF1NSD2CASP3SENP8SENP7 | |
| SCHEMBL17137277 | 0.80 | KMO (0.36) | APAF1NSD2CASP3SENP8SENP7 | |
| SCHEMBL1536597 | 0.80 | TNF (0.48) | APAF1NSD2CASP3SENP8SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120035439-A | Lactic acid enhancing compounds and uses thereof | 格莱制药股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20220298138-A1 | ENZYME INHIBITORS | SYGNATURE DISCOVERY LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| EP-4017586-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114269431-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2021032933-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032933-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| EP-2793887-B1 | SULPHONYLAMINOPYRROLIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2015-10-21 | — | — | EP | disclosed |
| US-9150544-B2 | Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2015-10-06 | — | — | US | disclosed |
| US-20140329801-A1 | SULPHONYLAMINOPYRROLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2014-11-06 | — | — | US | disclosed |
| EP-2793887-A1 | SULPHONYLAMINOPYRROLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092756-A1 | SULPHONYLAMINOPYRROLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2013-06-27 | — | — | WO | disclosed |
| EP-2606893-A1 | Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2013-06-26 | — | — | EP | disclosed |
| US-20050107409-A1 | Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-19 | — | — | US | disclosed |
| WO-2004080970-A1 | NOVEL BICYCLIC AROMATIC COMPOUNDS, THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329801-A1 | SULPHONYLAMINOPYRROLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | F9, TFPI, SERPINC1 | APAF1 168/4885NSD2 1628/4885CASP3 1077/4885 |
| US-20220298138-A1 | ENZYME INHIBITORS | SERPINB1, CMA1, MAOB | APAF1 653/4885NSD2 2651/4885CASP3 1924/4885 |
| US-20050107409-A1 | Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions | F12, F2, F11 | APAF1 297/4885NSD2 4307/4885CASP3 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.